Question
In: Accounting
The following transactions relate to bond investments of Livermore Laboratories. The company’s fiscal year ends on...
The following transactions relate to bond investments of
Livermore Laboratories. The company’s fiscal year ends on December
31. Livermore uses the straight-line method to determine
interest.
2018
| July | 1 | Purchased $16 million of Bracecourt Corporation 10% debentures, due in 20 years (June 30, 2038), for $15.7 million. Interest is payable on January 1 and July 1 of each year. | ||
| Oct. | 1 | Purchased $30 million of 12% Framm Pharmaceuticals debentures, due May 31, 2028, for $31,160,000 plus accrued interest. Interest is payable on June 1 and December 1 of each year. | ||
| Dec. | 1 | Received interest on the Framm bonds. | ||
| Dec. | 31 | Accrued interest. |
2019
| Jan. | 1 | Received interest on the Bracecourt bonds. | ||
| June | 1 | Received interest on the Framm bonds. | ||
| July | 1 | Received interest on the Bracecourt bonds. | ||
| Sept. | 1 | Sold $15 million of the Framm bonds at 101 plus accrued interest. | ||
| Dec. | 1 | Received interest on the remaining Framm bonds. | ||
| Dec. | 31 | Accrued interest. |
2020
| Jan. | 1 | Received interest on the Bracecourt bonds. | ||
| Feb. | 28 | Sold the remainder of the Framm bonds at 102 plus accrued interest. | ||
| Dec. | 31 | Accrued interest. |
Required:
1. Prepare the appropriate journal entries for
these long-term bond investments.
2. By how much will Livermore Labs’ earnings
increase in each of the three years as a result of these
investments? (Ignore income taxes.)
Solutions
Expert Solution
| Date | Pariculars | Debit | Credit |
| July 1, 2018 | Investment - bracecourt Corp. 10% debentures | 15700000 | |
| Cash | 15700000 | ||
| Oct 1, 2018 | Investment - Framm Pharmaceuticals 12% debentures | 31160000 | |
| Interest Receivable (30000000*12%*4/12) | 1200000 | ||
| Cash | 32360000 | ||
| Dec 1, 2018 | Cash (30000000*12%*6/12) - (Interest on Framm Pharma) | 1800000 | |
| Interest Receivable | 1200000 | ||
| Interest Income | 600000 | ||
| Dec 31, 2018 | Interest receivables (16000000*10%*6/12) | 800000 | |
| Interest Income (interest on Bracecourt Corp) | 800000 | ||
| Jan 1, 2019 | Cash (interest on Bracecourt Corp) | 800000 | |
| Interest receivables (16000000*10%*6/12) | 800000 | ||
| June 1,2019 | Cash (30000000*12%*6/12) - (Interest on Framm Pharma) | 1800000 | |
| Interest Income | 1800000 | ||
| July 1, 2019 | Cash (interest on Bracecourt Corp) | 800000 | |
| Interest Income | 800000 | ||
| Sept 1, 2019 | Cash | 15600000 | |
| Loss on sale of investment | 430000 | ||
| Interest income | 450000 | ||
| Investment - Framm Pharmaceuticals 12% debentures | 15580000 | ||
| Sale proceed=15000000*101%=15150000 | |||
| Purchase price=31160000/2=15580000 | |||
| Loss on sale of investment=15580000-15150000=430000 | |||
| Accrued Interest=15000000*12%*3/12=450000 | |||
| Cash Received=Sale proceed + Accrued Interest | |||
| Dec 1 2019 | Cash (15000000*12%*6/12) - (Interest on Framm Pharma) | 900000 | |
| Interest Income | 900000 | ||
| Dec 31, 2019 | Interest receivables (16000000*10%*6/12) | 800000 | |
| Interest Income (interest on Bracecourt Corp) | 800000 | ||
| Jan 1, 2020 | Cash (interest on Bracecourt Corp) | 800000 | |
| Interest receivables (16000000*10%*6/12) | 800000 | ||
| Feb 28, 2020 | Cash | 15750000 | |
| Loss on sale of investment | 280000 | ||
| Interest income | 450000 | ||
| Investment - Framm Pharmaceuticals 12% debentures | 15580000 | ||
| Sale proceed=15000000*102%=15300000 | |||
| Purchase price=31160000/2=15580000 | |||
| Loss on sale of investment=15580000-15300000=280000 | |||
| Accrued Interest=15000000*12%*3/12=450000 | |||
| Cash Received=Sale proceed + Accrued Interest=15750000 | |||
| July 1, 2020 | Cash (interest on Bracecourt Corp) | 800000 | |
| Interest Income | 800000 | ||
| Dec 31, 2020 | Interest receivables (16000000*10%*6/12) | 800000 | |
| Interest Income (interest on Bracecourt Corp) | 800000 |
| Interest Income | Profit or loss on sale of investment | Total Income | |
| 2018 | 1400000 | 1400000 | |
| 2019 | 4750000 | -430000 | 4320000 |
| 2020 | 2050000 | -280000 | 1770000 |
Pls upvote if like the answer.
ekkarill92 answered 1 year agoRelated Solutions
The following selected transactions relate to liabilities of United Insulation Corporation. United’s fiscal year ends on...
The following selected
transactions relate to liabilities of United Insulation
Corporation. United’s fiscal year ends on December 31.
2021
Jan.
13
Negotiated a
revolving credit agreement with Parish Bank that can be renewed
annually upon bank approval. The amount available under the line of
credit is $20 million at the bank’s prime rate.
Feb.
1
Arranged a
three-month bank loan of $5 million with Parish Bank under the line
of credit agreement. Interest at the prime rate of 10% was...
The following selected transactions relate to liabilities of United Insulation Corporation. United’s fiscal year ends on...
The following selected transactions relate to liabilities of
United Insulation Corporation. United’s fiscal year ends on
December 31.
2021
Jan.
13
Negotiated a
revolving credit agreement with Parish Bank that can be renewed
annually upon bank approval. The amount available under the line of
credit is $24.0 million at the bank’s prime rate.
Feb.
1
Arranged a
three-month bank loan of $7.6 million with Parish Bank under the
line of credit agreement. Interest at the prime rate of 13% was...
The following selected transactions relate to liabilities of United Insulation Corporation. United’s fiscal year ends on...
The following selected transactions relate to liabilities of
United Insulation Corporation. United’s fiscal year ends on
December 31.
2021
Jan.
13
Negotiated a revolving credit agreement with Parish Bank that
can be renewed annually upon bank approval. The amount available
under the line of credit is $25.0 million at the bank’s prime
rate.
Feb.
1
Arranged a three-month bank loan of $2.0 million with Parish
Bank under the line of credit agreement. Interest at the prime rate
of 13% was...
The following selected transactions relate to liabilities of United Insulation Corporation. United’s fiscal year ends on...
The following selected transactions relate to liabilities of
United Insulation Corporation. United’s fiscal year ends on
December 31.
2018
Jan.
13
Negotiated a
revolving credit agreement with Parish Bank that can be renewed
annually upon bank approval. The amount available under the line of
credit is $20.0 million at the bank’s prime rate.
Feb.
1
Arranged a
three-month bank loan of $3.2 million with Parish Bank under the
line of credit agreement. Interest at the prime rate of 10% was...
The following selected transactions relate to liabilities of United Insulation Corporation. United’s fiscal year ends on...
The following selected transactions relate to liabilities of
United Insulation Corporation. United’s fiscal year ends on
December 31. 2018 Jan. 13 Negotiated a revolving credit agreement
with Parish Bank that can be renewed annually upon bank approval.
The amount available under the line of credit is $29.5 million at
the bank’s prime rate. Feb. 1 Arranged a three-month bank loan of
$7.2 million with Parish Bank under the line of credit agreement.
Interest at the prime rate of 7% was...
The Town of Quincy’s fiscal year ends on June 30. The following data relate to the...
The Town of Quincy’s fiscal year ends on June 30. The following
data relate to the property tax levy for the fiscal year ended June
30, 2017. The balance in Deferred Inflows—Property Taxes was
$68,000 at the end of the previous year. This was recognized as
revenue in the current year in a reversing journal entry. On July
1, 2016, property taxes in the amount of $8,650,000 were levied. It
was estimated that 0.5 percent would be uncollectible. The property...
The following selected circumstances relate to pending lawsuits for Erismus, Inc. Erismus’s fiscal year ends on...
The following selected circumstances relate to pending lawsuits
for Erismus, Inc. Erismus’s fiscal year ends on December 31.
Financial statements are issued in March 2022. Erismus prepares its
financial statements according to U.S. GAAP.
Required:
Indicate the amount Erismus would record as an asset, a liability
or if no accrual would be necessary in the following
circumstances.
1. Erismus is defending against a lawsuit.
Erismus's management believes the company has a slightly worse than
50/50 chance of eventually prevailing...
The following selected circumstances relate to pending lawsuits for Erismus, Inc. Erismus’s fiscal year ends on...
The following selected circumstances relate to pending lawsuits
for Erismus, Inc. Erismus’s fiscal year ends on December 31.
Financial statements are issued in March 2019. Erismus prepares its
financial statements according to U.S. GAAP.
Required:
Indicate the amount Erismus would record as an asset, liability, or
not accrued in the following circumstances.
1. Erismus is defending against a lawsuit.
Erismus's management believes the company has a slightly worse than
50/50 chance of eventually prevailing in court, and that if...
The following selected circumstances relate to pending lawsuits for Erismus, Inc. Erismus’s fiscal year ends on...
The following selected circumstances relate to pending lawsuits
for Erismus, Inc. Erismus’s fiscal year ends on December 31.
Financial statements are issued in March 2019. Erismus prepares its
financial statements according to IFRS.
Required:
Indicate the amount Erismus would record as an
asset, liability, or not accrued in the following
circumstances.
1. Erismus is defending against a lawsuit.
Erismus's management believes the company has a slightly worse than
50/50 chance of eventually prevailing in court, and that if it...
The following selected circumstances relate to pending lawsuits for Erismus, Inc. Erismus’s fiscal year ends on...
The following selected circumstances relate to pending lawsuits
for Erismus, Inc. Erismus’s fiscal year ends on December 31.
Financial statements are issued in March 2019. Erismus prepares its
financial statements according to U.S. GAAP. Required: Indicate the
amount Erismus would record as an asset, liability, or not accrued
in the following circumstances. 1. Erismus is defending against a
lawsuit. Erismus's management believes the company has a slightly
worse than 50/50 chance of eventually prevailing in court, and that
if it...
ADVERTISEMENT
ADVERTISEMENT
Latest Questions
- What 2 things happen to the melting point of a solid when an impurity is present?
- How Can Hominin Evolution be characterized as " mosaic evolution" Use examples of species from the...
- Absorption and Variable Costing Income Statements for Two Months and Analysis During the first month of...
- Mobile and wireless devices are being increasingly used in the Business Administration and Management Industry. write...
- What are the options that might be considered in relation to introducing flexible work practices? What...
- Question 2 : Aggregate Scores: Write a program that opens 2 files, quiz.txt, and hw.txt. The...
- Define the term symbiosis specifically as it applies in a biological context. Compare and contrast parasitism,...
ADVERTISEMENT